O
FBRX

OrbiMed’s Forte Biosciences FBRX Stock Holding History

OrbiMed’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5M Buy
1,577,705
+380,750
+32% +$9.03M 0.62% 46
2026
Q1 		$31M Hold
1,196,955
– – 0.61% 47
2025
Q4 		$32.6M Hold
1,196,955
– – 0.67% 45
2025
Q3 		$18M Hold
1,196,955
– – 0.42% 56
2025
Q2 		$15.5M Buy
1,196,955
+603,867
+102% +$5.2M 0.39% 49
2025
Q1 		$4.6M Sell
593,088
-6,912
-1% -$81.6K 0.11% 79
2024
Q4 		$13.6M Buy
+600,000
New +$7.14M 0.28% 65
2021
Q2 		– Sell
-6,387
Closed -$5.47M – 165
2021
Q1 		$5.47M Buy
6,387
+2,699
+73% +$2.21M 0.05% 140
2020
Q4 		$3.36M Sell
3,688
-9,931
-73% -$9.34M 0.03% 142
2020
Q3 		$16.5M Sell
13,619
-24,394
-64% -$16.2M 0.21% 94
2020
Q2 		$13.9M Buy
+38,013
New +$17M 0.2% 88

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed's FBRX Position: Q2 2026 in Review

OrbiMed increased its Forte Biosciences (FBRX) stake by 32% in Q2 2026, buying an estimated $9.03M and bringing the position to 1,577,705 shares worth $33.5M. The position accounts for 0.62% of the portfolio, ranked #46.

OrbiMed first reported a position in FBRX in Q2 2020 and has held it in 11 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • OrbiMed held 1,577,705 shares of Forte Biosciences worth $33.5M as of Q2 2026.
  • OrbiMed bought 380,750 Forte Biosciences shares in Q2 2026, an estimated $9.03M.
  • Forte Biosciences made up 0.62% of OrbiMed's portfolio in Q2 2026, its #46 holding.
  • OrbiMed first reported a position in Forte Biosciences in Q2 2020 and has held it in 11 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.